News
Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica
Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program collaboration agreement to apply L
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: BRAIN Biotech AG: BRAIN Biotech AG’s Akribion Genomics technology receives patent approval for its groundbreaking nuclease G-dase E®
Convatec Group PLC: Scrip Dividend - Total Issued Shares
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces that it is partnering with the U.S. Biomedical Advanced Research and Development
Evolva and Nice & Green agree on improvements to financing agreement
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the J.P
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
EQS-News: BRAIN Biotech AG: Scientist from BRAIN Biotech AG receives VAAM Innovation Award for the discovery of a novel CRISPR nuclease family
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024
OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the peer-reviewed publication in Annals of Oncology* of the randomized Phase 3 clinical
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:
-
Morgan Stanley 21st Annual Global Healthcare
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: MPH Health Care AG: Half-year result 2023
Poxel to Report 2023 First Half-Year Results and host a video conference on September 26, 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods
Charles River Laboratories International, Inc. (NYSE: CRL) and PathoQuest SAS, a leader in the development and provision of next-generation sequencing (NGS) testing services for biopharmaceuticals
Silence Therapeutics to Participate in September Investor Conferences
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
ICON plc to Present at the Baird Global Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird Global
Evolva receives approval for Veri-teTM Resveratrol in Thailand
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25th Annual
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system
Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma